Cure8 research brief
Markers of systemic inflammation (CRP and ESR) were consistently higher in people with obesity across Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis, suggesting body weight may influence inflammatory burden regardless of disease type.
Adults with Crohn’s disease or UC, clinicians treating IMIDs, and researchers interested in obesity–inflammation interactions
The researchers used longitudinal electronic health record data to examine adults with at least two BMI measurements over five years.
Compared with healthy-weight patients, those with obesity had substantially higher CRP (about 49–83% higher) and ESR (about 24–48% higher) at baseline; patients overweight with high-risk comorbidities had intermediate elevations. Ferritin showed little or no association with BMI.
The authors suggest excess adiposity may add to systemic inflammatory burden across multiple immune-mediated diseases and that weight optimization deserves further study as part of comprehensive care.
Findings come from an observational EHR-based cohort; associations can signal correlations but not prove that losing weight will change biomarker levels or clinical outcomes. The abstract lacks detailed information on medications, disease activity, or other confounders.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Eli Lilly and Company
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
